vimarsana.com

Latest Breaking News On - Therapeutic development - Page 13 : vimarsana.com

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

10x Genomics Stock: Sales Are Growing At A Rapid Rate But So Are Expenses (NASDAQ:TXG)

10x Genomics Stock: Sales Are Growing At A Rapid Rate But So Are Expenses (NASDAQ:TXG)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Navidea Biopharmaceuticals (NYSE:NAVB) Receives New Coverage from Analysts at StockNews com

StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Monday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE:NAVB opened at $0.05 on Monday. The firm’s fifty day moving average is $0.06 and its 200-day moving average is $0.07. Navidea Biopharmaceuticals […]

Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by StockNews com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report sent to investors on Sunday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance Shares of Navidea Biopharmaceuticals stock opened at $0.05 on Friday. The business has a fifty day simple moving average of $0.06 […]

Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Saturday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Up 2.0 % Shares of NAVB opened at $0.06 on Friday. Navidea Biopharmaceuticals has a 12-month low of $0.02 and a 12-month high […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.